+关注
Level5的呱太
暂无个人介绍
IP属地：四川
10
关注
0
粉丝
2
主题
0
勋章
主贴
热门
Level5的呱太
2020-04-02
$APT 20200409 11.0 CALL(APT)$
期权就是过山车
Level5的呱太
2020-04-29
severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了
吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3543609131664174","uuid":"3543609131664174","gmtCreate":1580515115006,"gmtModify":1737778434846,"name":"Level5的呱太","pinyin":"level5dgtlevel5deguatai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":10,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.19%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"四川","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":924080905,"gmtCreate":1588166662507,"gmtModify":1704366705707,"author":{"id":"3543609131664174","authorId":"3543609131664174","name":"Level5的呱太","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3543609131664174","authorIdStr":"3543609131664174"},"themes":[],"htmlText":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","listText":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","text":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924080905","repostId":"1108976612","repostType":2,"repost":{"id":"1108976612","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":923135785,"gmtCreate":1585764691347,"gmtModify":1704358943000,"author":{"id":"3543609131664174","authorId":"3543609131664174","name":"Level5的呱太","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3543609131664174","authorIdStr":"3543609131664174"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/APT\">$APT 20200409 11.0 CALL(APT)$</a>期权就是过山车","listText":"<a href=\"https://laohu8.com/S/APT\">$APT 20200409 11.0 CALL(APT)$</a>期权就是过山车","text":"$APT 20200409 11.0 CALL(APT)$期权就是过山车","images":[{"img":"https://static.tigerbbs.com/0e6536e3eb1ac88f9b698ba4127241d0","width":"1080","height":"1537"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/923135785","isVote":1,"tweetType":1,"viewCount":2709,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":923135785,"gmtCreate":1585764691347,"gmtModify":1704358943000,"author":{"id":"3543609131664174","authorId":"3543609131664174","name":"Level5的呱太","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3543609131664174","authorIdStr":"3543609131664174"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/APT\">$APT 20200409 11.0 CALL(APT)$</a>期权就是过山车","listText":"<a href=\"https://laohu8.com/S/APT\">$APT 20200409 11.0 CALL(APT)$</a>期权就是过山车","text":"$APT 20200409 11.0 CALL(APT)$期权就是过山车","images":[{"img":"https://static.tigerbbs.com/0e6536e3eb1ac88f9b698ba4127241d0","width":"1080","height":"1537"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/923135785","isVote":1,"tweetType":1,"viewCount":2709,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]希望您能在老虎社区玩得愉快、赚得开心！如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":924080905,"gmtCreate":1588166662507,"gmtModify":1704366705707,"author":{"id":"3543609131664174","authorId":"3543609131664174","name":"Level5的呱太","avatar":"https://static.tigerbbs.com/4a09124ab57f96953e357b27d7692b1f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3543609131664174","authorIdStr":"3543609131664174"},"themes":[],"htmlText":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","listText":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","text":"severe开放标签实验，5天10天未出现安全性风险变化，14天死亡率7％，已经算是很好的结论了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/924080905","repostId":"1108976612","repostType":2,"repost":{"id":"1108976612","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1588163821,"share":"https://www.laohu8.com/m/news/1108976612?lang=&edition=full","pubTime":"2020-04-29 20:37","market":"us","language":"zh","title":"吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1108976612","media":"老虎资讯综合","summary":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治","content":"<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2020-04-29 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><span>4月29日讯，<a href=\"https://laohu8.com/S/GILD\">吉利德科学</a>盘前停牌，</span>吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。<span>吉利德科学在德股价涨10%。</span></p><p><span>吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。</span></p><p><img src=\"https://static.tigerbbs.com/dee6cfb37e279131634eba2667eca5b1\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"GILD":"吉利德科学"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108976612","content_text":"4月29日讯，吉利德科学盘前停牌，吉利德科学的瑞德西韦新冠临床试验已达到主要评估指标。吉利德科学在德股价涨10%。吉利德科学：第二次简单试验的前600名患者的结果预计在5月底出炉。接受10天瑞德西韦治疗的患者与接受5天治疗的患者的临床状态出现了相似的改善。在意大利以外的地区，在研究的第14天，两个治疗组（5天和10天治疗组）的整体死亡率为7%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1636,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
